Exosomes Implication in PD1-PD-L1 Activation in OSAS

NCT ID: NCT03811600

Last Updated: 2023-02-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-03-03

Study Completion Date

2020-10-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An increased occurrence of cancer associated mortality has been described in patients with Obstructive Sleep Apnea Syndrome (OSAS). This association might be partially explained by an impaired cellular immune response that has been described in OSAS. Is has been suggested that OSAS impact immune cells by upregulation of the PD-1/PD-L1 pathway. Exosomes are small membrane vesicles released by numerous cells in the bloodstream. Exosomes have been shown to be implicated in cancer cells proliferation via a PD-1/PD-L1 pathway activation.

This study will evaluate exosomal PD-1/PD-L1 expression in patients with OSAS as compared to controls and will further investigate their impact on immune cells function and proliferation capacities.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sleep Apnea Syndromes, Obstructive Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

OSAS patients

45 patients investigated for suspected OSAS with an apnea hypopnea index ≥15 per hour

PD1/PD-L1 exosomal expression

Intervention Type DIAGNOSTIC_TEST

exosomal PD1/PD-L1 expression

Non OSAS patients

45 patients investigated for suspected OSAS with an apnea hypopnea index \<15 per hour

PD1/PD-L1 exosomal expression

Intervention Type DIAGNOSTIC_TEST

exosomal PD1/PD-L1 expression

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PD1/PD-L1 exosomal expression

exosomal PD1/PD-L1 expression

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients requiring a sleep recording for suspected OSAS

Exclusion Criteria

* Préviously treated OSAS
* Cancer past history
* Pregnant women
* Cognitif impairment
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Angers

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Laboratoire du Sommeil, Département de Pneumologie, CHU d'Angers

Angers, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019-A00029-48

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

XOR Levels in OSA Patients (XOR-OSA)
NCT06554496 RECRUITING NA
Fat Metabolism in OSA and COPD
NCT02157844 COMPLETED